CSL Behring
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$523.0M
Doctors Paid
32,759
Transactions
247,973
2024 Total
$88.1M
Payment Breakdown by Category
Research$422.5M (80.8%)
Consulting$69.1M (13.2%)
Travel$3.7M (0.7%)
Food & Beverage$3.5M (0.7%)
Royalty/License$2.8M (0.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $422.5M | 39,119 | 80.8% |
| Consulting Fee | $69.1M | 52,972 | 13.2% |
| Honoraria | $9.6M | 3,505 | 1.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $7.0M | 3,050 | 1.3% |
| Travel and Lodging | $3.7M | 9,102 | 0.7% |
| Food and Beverage | $3.5M | 128,199 | 0.7% |
| Grant | $3.2M | 146 | 0.6% |
| Royalty or License | $2.8M | 83 | 0.5% |
| Space rental or facility fees (teaching hospital only) | $1.1M | 668 | 0.2% |
| Education | $385,452 | 11,106 | 0.1% |
| Charitable Contribution | $115,320 | 20 | 0.0% |
| Gift | $442.60 | 3 | 0.0% |
Payments by Type
Research
$422.5M
39,119 transactions
General
$100.5M
208,854 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome | $149.7M | 2 | 10,742 |
| A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE1116 (4-Factor Prothrombin Complex Concentrate [Kcentra / Beriplex]) to Improve Survival in Patients With Traumatic Injury and Acute Major Bleeding | $44.9M | 0 | 1,940 |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adults With Dermatomyositis (DM) | $31.2M | 8 | 2,418 |
| A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | $29.6M | 2 | 3,865 |
| Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | $27.3M | 1 | 3,765 |
| Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection AMR in Adult Renal Transplant Recipients | $19.7M | 0 | 409 |
| A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) | $13.5M | 3 | 1,397 |
| A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Trial of Alpha 1 - Antitrypsin (AAT) Combined With Corticosteroids vs Corticosteroids Alone for the Treatment of High Risk Acute Graft-versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell Transplant | $9.1M | 0 | 856 |
| A Double-blind, Randomized-withdrawal, Placebo-controlled Study to Evaluate the Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection in Adult Renal Transplant Recipients | $5.1M | 0 | 300 |
| A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients | $4.1M | 1 | 4,773 |
| A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema | $4.1M | 2 | 274 |
| City of Hope Process Development Agreement | $4.0M | 0 | 3 |
| A Phase 2a, Double-blind, Randomized, Placebo-controlled, Proof of Concept Study of Vascular Endothelial Growth Factor (VEGF)-B Blockade With the Monoclonal Antibody CSL346 in Subjects With Diabetic Kidney Disease | $4.0M | 0 | 1,510 |
| A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-arm Study to Investigate the Efficacy and Safety of Subcutaneous Administration of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema | $2.8M | 0 | 333 |
| A Phase 2, Multicenter, Double Blind, Randomized, Placebo-Controlled Study to Evaluate CSL312 in Coronavirus Disease 2019 (COVID 19) | $2.7M | 0 | 302 |
| CD34 Gene Editing | $2.4M | 0 | 6 |
| An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema | $2.2M | 8 | 708 |
| A Randomized, Double-blind, Placebo-controlled, Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of CSL312 in Subjects With Idiopathic Pulmonary Fibrosis | $2.2M | 0 | 930 |
| CSL112_3001 | $2.0M | 0 | 5 |
| An Observational Cohort Study of the Risk of Thromboembolic Events Among Adult Patients Treated With KCENTRA Compared With Plasma for Urgent Reversal of Vitamin K Antagonist Therapy in the Setting of Acute Major Bleeding | $1.7M | 0 | 8 |
| Randomized Study of Single vs. Multiple Privigen Dose Regimens in Pediatric CIDP | $1.4M | 3 | 300 |
| The Safety and Efficacy of Alpha-1 Antitrypsin AAT for the Prevention of GraftVersus-host Disease GVHD in Patients Receiving Hematopoietic Cell Transplant MODULAATE | $1.3M | 0 | 177 |
| A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV)(CMV) | $1.2M | 0 | 56 |
| Autologous Transplantation and Stem Cell-Based Gene Therapy With LVsh5C46 CAL-1, a Dual Anti-HIVLentiviral Vector, for the Treatment ofHIV-Associated Lymphoma | $1.1M | 0 | 26 |
| Scientific Education Inititative | $1.1M | 0 | 49 |
| Human C1 Esterase Inhibitor (C1-INH) in Subjects With Acute Abdominal or Facial Hereditary Angioedema (HAE) Attacks | $1.1M | 0 | 10 |
| Research Support for A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome | $1.1M | 0 | 10 |
| A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Trial of Alpha 1 - Antitrypsin (AAT) Combined With Corticosteroids vs Corticosteroids Alone for the Treatment of High Risk Acute Graft-versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell Transplant (BMT CTN 1705) | $1.1M | 0 | 34 |
| CSL Collaborative Research Agreement (XLA) Gen1 | $1.1M | 0 | 2 |
| An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A | $1.1M | 0 | 116 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2022 |
|---|---|---|---|---|
| Dr. Amy Schmidt, Md, Phd, MD, PHD | Blood Banking & Transfusion Medicine | Denver, CO | $2.9M | $0 |
| Majed Refaai, Md, MD | Clinical Pathology | Rochester, NY | $2.2M | $0 |
| Dr. Kwabena Oteng, M.d, M.D | Family Medicine | Springdale, OH | $1.6M | $0 |
| Dr. Richard Tanner, M.d, M.D | Family Medicine | Indianapolis, IN | $1.4M | $0 |
| Mr. Andrzej Kalinski, M.d, M.D | Multi-Specialty | Rock Hill, SC | $1.3M | $0 |
| Michael Gibson, M.d, M.D | Internal Medicine | Smyrna, GA | $1.2M | $0 |
| Christopher Jennings, Md, MD | Internal Medicine | Anderson, SC | $1.1M | $0 |
| Mr. Loren Chudler, Do, DO | Emergency Medical Services | Southfield, MI | $1.1M | $0 |
| Manuel Mendoza, M.d, M.D | Specialist | Brownsville, TX | $1.1M | $0 |
| Ray Fernandez, M.d, M.D | Independent Medical Examiner | Corpus Christi, TX | $1.1M | $0 |
| Dr. Stephen Martin, M.d, M.D | Emergency Medicine | Marietta, GA | $1.0M | $0 |
| Jodi Parks, M.d, M.D | Clinical Pathology/Laboratory Medicine | Indianapolis, IN | $1.0M | $0 |
| Kenneth Primm, M.d, M.D | Anesthesiology | Crawfordsville, IN | $1.0M | $0 |
| John Mckinney, Do, DO | Emergency Medicine | Tyler, TX | $970,644 | $0 |
| Unknown Provider | — | — | $909,763 | $0 |
| Dr. Anil Prasad, M.d, M.D | General Practice | Taylor, MI | $816,254 | $0 |
| Yanzheng Zhang, Md, MD | Clinical Laboratory Director, Non-physician | Zachary, LA | $812,089 | $0 |
| Hank Hanna, Md, MD | Hematology | Albuquerque, NM | $769,138 | $0 |
| Dr. Suzanne Bertram, Md, MD | Otolaryngology | Fort Collins, CO | $741,208 | $0 |
| Dr. John Ticehurst, M.d, M.D | Clinical Pathology/Laboratory Medicine | Glen Burnie, MD | $740,983 | $0 |
| Matthew Cooper, M.d, M.D | Thoracic Surgery (Cardiothoracic Vascular Surgery) | Tulsa, OK | $733,058 | $0 |
| Neil Caliman, Md, MD | Anatomic Pathology & Clinical Pathology | Lansing, MI | $714,236 | $0 |
| Dr. Raffi Tachdjian, M.d, M.D | Pediatric Allergy/Immunology | Santa Monica, CA | $668,100 | $0 |
| Dr. Deborah Martin, Md, MD | General Practice | Loveland, CO | $641,464 | $0 |
| Dr. Paul Shrode | General Practice | Missouri City, TX | $625,607 | $0 |
Ad
Top Products
- Kcentra $56.0M
- Hizentra $42.7M
Associated Products (26)
- Kcentra $56.0M
- Hizentra $42.7M
- Berinert $26.5M
- Zemaira $24.0M
- Haegarda $9.6M
- Privigen $2.6M
- Idelvion $2.3M
- Multiple Products $2.2M
- Cytogam $2.1M
- HEMGENIX $1.8M
- Afstyla $1.8M
- Berinert 500U $1.6M
- Cytogam 2.5g $1.1M
- Hizentra 20 ml (4g) $517,440
- Privigen 10g $167,280
- Albumin $111,065
- Privigen 20g $106,080
- Humate-P $98,660
- Rhophylac $66,310
- Riastap $65,555
- RiaSTAP $56,758
- Corifact (1000-1600 IU) $42,055
- Hemgenix $30,258
- AlbuRx 5% 250 ml $26,370
- Kcentra 800-1240 IU $25,380
- Albuminar-25 $10,792
Payment Categories
- Food & Beverage $3.5M
- Consulting $69.1M
- Travel & Lodging $3.7M
- Research $422.5M
- Royalties $2.8M
About CSL Behring
CSL Behring has made $523.0M in payments to 32,759 healthcare providers, recorded across 247,973 transactions in the CMS Open Payments database. In 2024, the company paid $88.1M. The top product by payment volume is Kcentra ($56.0M).
Payments were distributed across 251 medical specialties. The top specialty by payment amount is Family Medicine ($11.5M to 878 doctors).
Payment categories include: Food & Beverage ($3.5M), Consulting ($69.1M), Research ($422.5M), Travel & Lodging ($3.7M), Royalties ($2.8M).
CSL Behring is associated with 26 products in the CMS Open Payments database, including Kcentra, Hizentra, and Berinert.